BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30637710)

  • 1. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new hope: the immunotherapy in small cell lung cancer.
    Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
    Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
    Tian Y; Zhai X; Han A; Zhu H; Yu J
    J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for small cell lung cancer: mechanisms of resistance.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2019 May; 19(5):423-432. PubMed ID: 30855195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Apr; 11(6):457-460. PubMed ID: 30860440
    [No Abstract]   [Full Text] [Related]  

  • 13. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances of immunotherapy in small cell lung cancer].
    Liu J; Zhang S; Li H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):474-80. PubMed ID: 24949688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
    J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.
    Chae YK; Pan A; Davis AA; Mohindra N; Matsangou M; Villaflor V; Giles F
    Clin Lung Cancer; 2017 Mar; 18(2):132-140. PubMed ID: 27520630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of targeted and immune therapies in SCLC.
    Hendriks LEL; Menis J; Reck M
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.